First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
Trial Details
- NCT ID
- NCT06797999
- Phase
- PHASE1 / PHASE2
- Sponsor
- Adcendo ApS
- Status
- RECRUITING
- Cancer Type
- Sarcoma
- Interventions
- Antibody-drug conjugate (ADC)
- Locations (sample)
- Aurora, Colorado, United States|39.72943,-104.83192
- Miami, Florida, United States|25.77427,-80.19366
- New York, New York, United States|40.71427,-74.00597
- Houston, Texas, United States|29.76328,-95.36327
- Leuven, Belgium|50.87959,4.70093
Key Eligibility Criteria
- ≥ 18 years of age
- Histologically confirmed STS with metastatic and/or unresectable disease (not amenable to treatment with curative intent).
- Prior treatment with at least one but no more than two lines of cytotoxic systemic therapy for metastatic/unresectable disease.
- Measurable disease as per RECIST v 1.1.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Sarcoma Trials on Trialify →